

**Institution:** University of California-San Diego Center for AIDS Research (CFAR)  
La Jolla, California, USA  
<http://id.ucsd.edu/international/> and <http://cfar.ucsd.edu/>

**Contacts:** Robert T. Schooley  
Professor  
rschooley@ucsd.edu

Kimberly Schafer  
CFAR Administrative Director  
kschafer@ucsd.edu

## LAB RESOURCES

---

**Please indicate and briefly whether your institution provides any of the following core lab services or facilities to African investigators (select all that apply):**

*Animal lab and/or non-human primate research facility:*

*BSL-3 lab space and equipment:* Training and collaborative research support available

*Bacteriology:* Training and collaborative research support available

*Clinical Chemistry:*

*DNA sequencing:* Training and collaborative research support available

*Flow cytometry:* Training and collaborative research support available

*Genomics:* Training and collaborative research support available

*Immunology/immunopathogenesis:* Training and collaborative research support available

*Pathology:* Training and collaborative research support available

*Pharmacology/analytical chemistry:*

*Virology/molecular biology:* Training and collaborative research support available

*Other:* Protein expression and proteomics, molecular biology

## BIOLOGICAL SPECIMEN BANKING/REPOSITORY

---

**Please briefly describe the stored biological specimens available through your institute:**

- Various well characterized viral samples

**Please indicate whether your institution provides any of the following equipment or resources to African investigators (select all that apply):**

*-80C freezers* yes

*Nitrogen storage tanks*

*Specimen samples (described above)*

*Other*



## **BIostatistical/Data Management Support**

---

Please indicate whether your institution provides any of the following core services to African investigators (select all that apply):

- Computational biology
- Biomathematical modeling
- Bioinformatics/biometrics

## **Technical Assistance, Consultation, and Support**

---

Please indicate whether your institution provides any of the following specialized technical expertise or support to African investigators (select all that apply):

- Clinical Research/Population Sciences
- Health Services/Health Education
- Social and Behavioral Sciences/Prevention
- Developmental Support (e.g., logistical, operational and infrastructure support, small pilot grants)

## **Training and Education**

---

Does your institution offer degree and/or non-degree training to African scholars?

- Yes

Please indicate whether your institution offers any of the following research training programs that may be of relevance or interest to African investigators (select all that apply):

- Bioinformatics
- Clinical Research (e.g., Clinical Research Scholars & Fellows Program)
- Translational and/or Operational Research in Comorbidities (ICOHRTA)

## **Collaborations**

---

Please list and briefly describe your current collaboration with any African institutions for either research or training purposes.

- Medical Education Partnership Initiative (MEPI) with the Universidade Eduardo Mondlane in Maputo, Mozambique and with Addis Ababa University, and selected other Ethiopian medical schools.
- We also have ongoing collaborations in Zimbabwe, South Africa, Kenya, and Cameroon.

Please describe your plans for future collaborations within African (additional groups, sites, countries, etc.)

- We plan to continue all existing collaborations with African institutions and expand as possible.

**Please list and briefly describe your institution's collaborations and/or partnerships with entities outside of Africa (e.g., organizations and networks in the USA, Europe, etc. – including CFARS, NIH clinical trials networks, HPTN, HVTN, AMC, leDEA, USAID, PEPFAR, etc.**

- We have collaborations and/or partnerships with many other CFARs, ACTG, AMC, PEPFAR, and leDEA.

## **CLINICAL COHORTS**

---

**Do you have access to existing clinical cohorts in Africa or USA?**

- Yes

**Please describe each existing clinical cohort that you have access to, including specifics like “HIV-TB infected HAART naïve adults”, sample size, sample type, sex, age, and whether clinical samples are currently being collected and/or stored (specify which samples).**

- Via collaboration through the ACTG sample repository

**Are you planning to establish any new clinical cohorts over the next 5 years?**

- Yes

**Please describe the clinical cohorts that you are planning to establish, including specifics such as “HIV-TB infected HAART naïve adults”, sample type, sex, and age.**

- HIV-TB infected individuals.
- HIV-*P. falciparum* infected individuals